Möchten Sie immer auf dem neuesten Stand bleiben?

After successful completion of FDA Type C meeting, Clene expects to submit an NDA for CNM-Au8® under the accelerated approval pathway in the third quarter of 2026In January 2026, Clene completed an...

Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansionContinued advancement of pharmaceutical pipeline, medical affairs initiatives and international...

Dynacor Group Inc. announces its unaudited financial and operational results for the first quarter ended March 31, 2026.

Global Genomic Medicine Market to reach USD 123 billion by 2035, driven by rising cancer cases and growing adoption of precision medicine.

Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV® study presented today at ASGCT 2026 Annual Meeting along with initial...

Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 millionInvivyd in vitro data showed continued...

First Quarter Revenue was $647.9 million, a 15.9% increase over the prior year periodFirst Quarter Net income was $41.7 million compared to $5.2 million for the prior year periodAdjusted EBITDA for Q1...

American Shared Hospital Services Reports First Quarter 2026 Financial Results

MONTREAL, May 14, 2026 (GLOBE NEWSWIRE) -- Aya Gold & Silver Inc. (TSX: AYA; NASDAQ: AYA) (“Aya” or the “Corporation”) today announced its financial and operational results for the first quarter...

MONTREAL, May 14, 2026 (GLOBE NEWSWIRE) -- Boralex Inc. (“Boralex” or the “Corporation”) (TSX: BLX) is pleased to report its results for the first quarter of fiscal 2026. Highlights Financial...